GlioMethyl – Promotor methylation of the DUSP-4 gene as predictive parameter for gliomas
Gliomas, especially secondary glioblastomas, are affected
with hypermethylation of the promoter region of the DUSP4 gene. Further studies have shown a significant correlation between hypermethylation of DUSP4 and prolonged survival of glioblastoma patients. Similar correlation has also been observed with MGMT promoter methylation and treatment of Glioblastoma patients with alkylating agents. The present invention therefore provides a predictive epigenetic parameter for diagnosis or prognosis of gliomas and may be useful for prediction of the responsiveness to certain therapies. It further describes an improved method for the determination of the promoter methylation, which is applicable for the clinical setting. This invention provides an opportunity for the development of therapeutics for secondary glioblastomas.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
